AuraSonics is not a better stethoscope. It is a new sensing modality — a soft wearable that listens to the heart from three thousand points at once, captures the energy a microphone can't feel, and hands a physician an objective, spatially mapped, AI-readable picture of the cardiac field.
A new category: Wearable Cardiac Tomography.
Every auscultation tool before it captured acoustic pressure, typically at a single point. AuraSonics captures two physically different energies at the same instant — through two complementary sensor types in one belt.
The failing heart often moves before it sounds — and a microphone on the chest can't feel that motion, because it rides along with it. We capture both.
Heart sounds, murmurs, valve vibration, turbulent-flow signatures — high-resolution pressure waves.
Systolic thrust, chest-wall recoil, ventricular filling, heart-rocking — the physical movement a mic cannot feel.
A stethoscope hears a single local projection of the heart. AuraSonics wraps the torso in a soft belt of 20 rings × 150 patches = 3,000 individually addressable sensors, each reporting where, when, and how the chest wall moves and sounds.
Each patch is a tuned LC resonator. A faint physiological event produces a vanishingly small capacitance change that ordinary electronics would lose in noise. Our resonator converts it into a large, clean frequency shift — gain built into the physics, before a single line of software runs.
We never amplify a sound — there is nothing to amplify. Motion shifts each resonator's frequency; a digital counter simply counts the shift, resolving every event into a compact 16-bit signature.
We don't listen to the heart.
We measure it.
Every patch is tuned to its own frequency, so the entire array is read at once — wirelessly, crosstalk-free. One sweep. Three thousand answers.
With sound arriving at 3,000 known coordinates, the AI solves the inverse problem: it triangulates the origin of a signature through tissue-aware propagation and renders it on a patient-specific thoracic map — to a modeled accuracy of 1–3 mm, enough to distinguish mitral from tricuspid, aortic from pulmonic.
A signal can say something is wrong. A field is designed to say where.
AuraSonics builds a digital twin — an age-, sex-, and anatomy-matched simulation of a healthy thorax, computed patch-by-patch across all 3,000 locations. The patient's live reading is subtracted from it.
What remains is a pure deviation map — the exact signature of what is different, where, and by how much. This is the objective, reproducible reference the stethoscope never had.
AuraSonics pairs networks that read the texture of each signal with networks that model how energy propagates across the array — then fuses it with labs and history into a probability-weighted, physician-reviewable assessment.
3,000 patches, two energy types, microsecond-resolved.
Spectrogram features — S1–S4, murmurs, crackles.
Array as a graph — spatial spread & source paths.
+ labs, history, prior baselines → probability.
Spatio-spectral hotspots, confidence, review.
Every score is traceable to the patches, frequencies, and timing that produced it — and a clinician always reviews and approves. Explainable by design, which is exactly what regulators want to see.
Coordinate-aligned, precisely time-stamped scans let the same heart be compared against itself across months and years — tracking disease progression, treatment response, and post-procedure healing. The stethoscope forgets every visit. AuraSonics is built to remember all of them.
Every medicine is a molecule, and every molecule that reaches the bloodstream changes the heart — the force of its contraction, the behavior of its valves, the timing of its rhythm. Each change leaves a mark. Every mark can be read.
So we hold each patient against their perfect twin — the same heart, rendered in flawless health by the same three-thousand-point field — and we measure the distance. We call it the delta. Then we watch which way it moves. No marketing claim, no placebo, no wishful thinking survives that comparison.
"Whatever enters the bloodstream returns a verdict."
A drug, a supplement, a lungful of clean air or of smog — nothing the body takes in leaves the heart unchanged, and nothing escapes the field.
Before any compound has time to act, the first scan already shows how far the real heart stands from its own ideal — the baseline delta.
Week by week the portrait moves. A therapy that helps closes the delta; one that harms widens it. From that motion alone: benefit or harm.
Illustrative and hypothetical — development-stage, not clinically validated. The same twin-and-delta principle extends beyond the acoustic field: every modality we add carries its own standard of perfect health.
Most aortic dissections strike below the size guidelines operate on — and the scans that watch these patients come months to years apart. Nothing observes the space between them. The degeneration is silent; too often, the first symptom is the catastrophe itself.
AuraSonics is designed for exactly this interval: continuous, self-referenced surveillance where a trajectory beats a snapshot — a rising deviation against the patient's own baseline, crossing an action threshold in time to act.
“The belt earns the CT; the CT earns the surgery.”
A rising, non-transient deviation trajectory crosses the action threshold — automated and probability-weighted.
A clinician-reviewable alert: “high, and rising — recommend confirmatory imaging.”
Definitive testing is ordered — CT angiography, transesophageal echo, and/or MRI.
Imaging confirms or refutes a high-risk aneurysm. No one is asked to act on an acoustic signal alone.
If confirmed and indicated — an elective repair, before rupture.
Illustrative and hypothetical — development-stage, not clinically validated. AuraSonics is a triage-and-timing layer that routes the right patient to definitive imaging; it never replaces it. Our standard is validation-first.
The best-funded names still optimize the same narrow signal: acoustic energy, at one or a few points. Eko raised over $150M to connect a single sensor to AI — one energy, where AuraSonics captures two.
And they share one blind spot by physics: a sensor that rides the chest cannot feel the heart's motion. AuraSonics resolves the motion they ride over.
Comparison reflects AuraSonics' engineering targets against publicly available specifications of commercially deployed devices. AuraSonics is development-stage and not yet clinically validated.
They are improving auscultation. We are replacing it with a measurement.
The advantage isn't a single trick — it's an interlocking architecture, each layer hard to invent and harder to design around. Cardiology is the beachhead; the same sensing field extends to pulmonary, vascular, and beyond.
Dual-channel Type A / Type B LC-resonant patches, frequency-division readout, and high-density spatial sensing across the torso.
CNN + GNN analysis of heart-sound components and propagation, generating spatio-spectral maps and abnormality inference.
Patient-specific healthy baseline, deviation mapping, and synthesis with clinical data into a longitudinal, treatment-aware record.
AuraSonics is a development-stage company. The technology described is the subject of pending provisional patent applications; performance figures such as >70 dB SNR and 1–3 mm localization are engineering and modeled targets, not yet clinically validated. AuraSonics products are not FDA-cleared and are not available for clinical use.